Clinical Trial Update: A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial comparing intravenous iron isomaltoside 1000 (Monofer) to placebo has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• Monofer (Ferric derisomaltose)

Snippet

Sponsor: Pharmacosmos A/S | Conditions: Iron Deficiency Anemia | Phase 3 | Status: WITHDRAWN